<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2026-02-02 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2026-02-02/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2026-02-02"><meta property="og:description" content="ğŸ“… Daily Report - 2026-02-02 ä»Šæ—¥ç­›é€‰å‡º 74 æ¡å†…å®¹ï¼Œæ¥è‡ª 1 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2026-02-02T00:00:00+00:00"><meta property="article:modified_time" content="2026-02-02T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week052026"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2026-02-02"><meta itemprop=description content="ğŸ“… Daily Report - 2026-02-02 ä»Šæ—¥ç­›é€‰å‡º 74 æ¡å†…å®¹ï¼Œæ¥è‡ª 1 ä¸ªæ¥æº"><meta itemprop=datePublished content="2026-02-02T00:00:00+00:00"><meta itemprop=dateModified content="2026-02-02T00:00:00+00:00"><meta itemprop=wordCount content="2276"><meta itemprop=keywords content="Research,Daily,Week052026"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2026-02-02"><meta name=twitter:description content="ğŸ“… Daily Report - 2026-02-02 ä»Šæ—¥ç­›é€‰å‡º 74 æ¡å†…å®¹ï¼Œæ¥è‡ª 1 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2026-02-02</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2026-02-02T00:00:00Z>2026-02-02</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2026-02-02>ğŸ“… Daily Report - 2026-02-02</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>74</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>1</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
Xeniumç©ºé—´è½¬å½•ç»„æŠ€æœ¯é¦–æ¬¡åº”ç”¨äºæ—©æœŸèƒšèƒå‘è‚²åŠè¾èˆå°¾éƒ¨å†ç”Ÿç ”ç©¶ã€‚ microRNA-25é€šè¿‡Syndecan3è°ƒæ§å…ˆå¤©å’Œä½“æ¶²å…ç–«ï¼Œæ­ç¤ºäº†å…¶åœ¨å…ç–«æ£€æŸ¥ç‚¹æ²»ç–—è€è¯ä¸­çš„å…³é”®ä½œç”¨ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>ç™Œç—‡ä¾µè¢­ä¸å…ç–«æµ¸æ¶¦ï¼šCSN3åœ¨èƒƒç™Œä¸­ä¿ƒè¿›ä¾µè¢­å¹¶å½±å“å…ç–«æµ¸æ¶¦ã€‚</li><li>å…ç–«æ²»ç–—è€è¯æœºåˆ¶ï¼šmicroRNA-25åœ¨å°é¼ æ¨¡å‹ä¸­é€šè¿‡Syndecan3ä»‹å¯¼å…ç–«æ£€æŸ¥ç‚¹æ²»ç–—è€è¯ã€‚</li><li>å‘è‚²ç”Ÿç‰©å­¦ä¸å†ç”Ÿï¼šåˆ©ç”¨XeniumæŠ€æœ¯è§£æè¾èˆèƒšèƒå’Œå°¾éƒ¨å†ç”Ÿè¿‡ç¨‹çš„ç»†èƒå¼‚è´¨æ€§ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>Xeniumç©ºé—´è½¬å½•ç»„æŠ€æœ¯ï¼šå®ç°é«˜åˆ†è¾¨ç‡çš„ç©ºé—´åŸºå› è¡¨è¾¾åˆ†æã€‚</li><li>æ•´åˆå¤šç»„å­¦æ–¹æ³•ï¼šç»“åˆRNA-seqã€ATAC-seqç­‰æŠ€æœ¯æ·±å…¥è§£æåˆ†å­æœºåˆ¶ã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (74æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE317661 CSN3ä¿ƒè¿›èƒƒç™Œä¾µè¢­ï¼Œå¹¶é€šè¿‡æ¿€æ´»NOD/TLRé€šè·¯ä¸å…ç–«æµ¸æ¶¦ç›¸å…³</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€TLR</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Gang Wang ; Dalai Xu ; Lei Qiu ; Feng Lu ; Yongchang MiaoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe found that CSN3 is highly expressed in gastric cancer and is associated with advanced tumor stage, lymph node metastasis, and poor prognosis. Functional assays showed that CSN3 promotes proliferation and migration while inhibiting apoptosis in GC cells. RNA-sequencing revealed that CSN3 overexpression predominantly activates innate immuneâ€“related pathways, particularly the NOD-like receptor and Toll-like receptor signaling pathways, suggesting a role for CSN3 in inflammatory and immune remodeling of the tumor microenvironment. Consistently, CSN3 expression was positively correlated with B-cell and CD8âº T-cell infiltration, indicating that CSN3-driven transcriptional programs may link tumor aggressiveness with immune microenvironment alterations.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317661">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE313338 Xenium ç©ºé—´è½¬å½•ç»„å­¦ç ”ç©¶ 28 æœŸèƒšèƒå’Œå†ç”Ÿ 3 å˜ç±³å¢¨è¥¿å“¥é’å£èˆå°¾å·´ï¼ˆ3ã€7ã€10ã€14 å¤©åï¼‰ï¼ŒåŒ…æ‹¬æˆç†Ÿçš„æœªæˆªå°¾å°¾å·´</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Vijayishwer S Jamwal ; Riley Grindle ; Ryan P Seam ; Fred Kolling ; Prayag Murawala ; Joel GraberSeries Type : OtherOrganism : Ambystoma mexicanum100 genes were selected, including cell-specific markers, transcription factors and signalling molecules, to understand tail patterning and gene oscillations in the embryo and in comparison to the tail.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313338">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE313080 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Non-coding RNA profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313080">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE313005 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [single_clone_RNA_seq_B16]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant &ldquo;cold&rdquo; tumors into immune responsive &ldquo;hot&rdquo; tumors, offering therapeutic avenues to enhance cancer immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313005">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE313004 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [single_cell_RNA_seq_MC38]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant &ldquo;cold&rdquo; tumors into immune responsive &ldquo;hot&rdquo; tumors, offering therapeutic avenues to enhance cancer immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313004">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE313003 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [In_vitro_RNA_seq_B16]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant &ldquo;cold&rdquo; tumors into immune responsive &ldquo;hot&rdquo; tumors, offering therapeutic avenues to enhance cancer immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313003">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE313002 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [Bulk_tumor_RNA_seq_B16]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Lingling Wang ; Hui Hui ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant &ldquo;cold&rdquo; tumors into immune responsive &ldquo;hot&rdquo; tumors, offering therapeutic avenues to enhance cancer immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313002">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>GSE313001 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [small_RNA_seq_B16]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Gulshanbir Baidwan ; Hui Hui ; Tariq M RanaSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant &ldquo;cold&rdquo; tumors into immune responsive &ldquo;hot&rdquo; tumors, offering therapeutic avenues to enhance cancer immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313001">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>GSE309890 æŠ—æŠ‘éƒè¯èˆæ›²æ—é€šè¿‡åº”æ¿€é©±åŠ¨çš„ç£·é…¸æˆŠç³–é€”å¾„é‡ç¼–ç¨‹å¯¼è‡´è€è¯æ€§äº§ç”Ÿï¼štktA ä½¿ä»£è°¢å›æ»š</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€resistanceã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yueting Cui ; Shiyuan Xue ; Jianhua Guo ; Chengdong ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Escherichia coli str. K-12 substr. MG1655Selective serotonin reuptake inhibitors (SSRIs) may accelerate antibiotic resistance, but the metabolic changes behind this processâ€”and how to restore susceptibilityâ€”are still not well understood. We demonstrated that sertraline led to a biased resistance profile in Escherichia coli, characterized by early accumulation of mutations targeting rifampicin and ciprofloxacin. These genetic alterations were linked to a compensatory respiratory mechanism dependent on Complex I, leading to reduced nicotinamide adenine dinucleotide and superoxide/hydrogen peroxide buildup. They also caused a rapid shift of glucose from glycolysis to the pentose-phosphate pathway (PPP) to produce reduced nicotinamide adenine dinucleotide phosphate during oxidative stress, similar to paraquat-like redox stress. Inhibiting the non-oxidative PPP, especially transketolase A (tktA), eliminated the sertraline-primed advantage and brought back antibiotic susceptibility, decreasing survival by approximately 10,000 times during antibiotic challenge, even with rpoBC and gyrAB mutations fixed. These findings uncover an electron transfer chain/PPPâ€“coupled redox module as the hidden driver behind sertraline-induced resistance, highlighting mutation-agnostic ways to restore bacterial sensitivity. By reframing SSRI-induced resistance as a modifiable metabolic trait, we provide a basis for using metabolic adjuvants to shield the millions of SSRI users from the unintended risk of antibiotic resistanceâ€”transforming a pharmacological challenge into a manageable, reversible target</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309890">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> â­ <strong>GSE266852 åˆ©ç”¨å•ç»†èƒè½¬å½•ç»„æµ‹åºåˆ†ææ¯”è¾ƒå¥åº·å¯¹ç…§è€…ã€ç±»é£æ¹¿æ€§å…³èŠ‚ç‚æ‚£è€…å’Œç‹¼ç–®æ‚£è€…è¡€æ¶² PBMC ä¸­çš„å·®å¼‚åŸºå› è¡¨è¾¾ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cellã€transcriptome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSingle-cell transcriptome sequencing was used to detect and compare differentially expressed genes in PBMCs from healthy controls in patients with rheumatoid arthritis, systemic lupus erythematosus patients.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266852">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 64 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>RNA-seq</td><td>11</td></tr><tr><td>immune</td><td>10</td></tr><tr><td>genome</td><td>9</td></tr><tr><td>cancer</td><td>9</td></tr><tr><td>tumor</td><td>7</td></tr><tr><td>resistance</td><td>7</td></tr><tr><td>transcriptome</td><td>6</td></tr><tr><td>immunity</td><td>6</td></tr><tr><td>sequencing</td><td>5</td></tr><tr><td>T cell</td><td>5</td></tr><tr><td>leukemia</td><td>5</td></tr><tr><td>ATAC-seq</td><td>4</td></tr><tr><td>epigenetic</td><td>4</td></tr><tr><td>transcriptomics</td><td>4</td></tr><tr><td>metabolic</td><td>3</td></tr><tr><td>pathway</td><td>3</td></tr><tr><td>single-cell</td><td>3</td></tr><tr><td>aging</td><td>2</td></tr><tr><td>monocyte</td><td>2</td></tr><tr><td>histone</td><td>2</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (64æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302731">GSE302731 å®¶è¢‹ç‹¸ä¸‰å±‚è„ä¾§è†œçš„å¾®é‡RNAæµ‹åºç ”ç©¶èƒç›˜ç»†èƒå› å­ä¿¡å·ä¼ å¯¼</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318164">GSE318164 åˆ†å­å¼‚è´¨æ€§å’Œå…ç–«æµ¸æ¶¦é©±åŠ¨ä¸Šå°¿è·¯å°¿è·¯ä¸Šçš®ç™Œçš„ä¸´åºŠç»“å±€</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317599">GSE317599 æŠ‘åˆ¶NEDDylationå¯é€šè¿‡çº¿ç²’ä½“è‡ªå™¬å»¶é•¿å¯¿å‘½å¹¶åœ¨è¡°è€è¿‡ç¨‹ä¸­ç»´æŒå¿ƒè„åŠŸèƒ½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316764">GSE316764 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [ATAC-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316618">GSE316618 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [Visium]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316616">GSE316616 ç»“è‚ ç‚å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314758">GSE314758 åŒæ—¶æµ‹é‡ç¿»è¯‘é€Ÿç‡å’Œè½¬å½•ç»„æ­ç¤ºäº†æ´»è·ƒç»†èŒç»†èƒç¾¤ä½“å†…çš„å…³è”è°ƒæ§ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313713">GSE313713 NSD2 é€šè¿‡ Hippo ä¿¡å·é€šè·¯çš„è¡¨è§‚é—ä¼ è°ƒæ§é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313573">GSE313573 å˜å½¢è™«æ ·é—´è´¨è½¬åŒ–å’Œç™Œç—‡ä¾µè¢­å¯å¡‘æ€§çš„è›‹ç™½æ°´è§£æ§åˆ¶ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313572">GSE313572 å˜å½¢è™«æ ·é—´è´¨è½¬åŒ–å’Œç™Œç—‡ä¾µè¢­å¯å¡‘æ€§çš„è›‹ç™½æ°´è§£æ§åˆ¶ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308747">GSE308747 TCR-SUB1-DOCK2 ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚ CD4+ T ç»†èƒè¿ç§»èƒ½åŠ›æ¥æ§åˆ¶è‡ªèº«å…ç–« [ATAC-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308746">GSE308746 TCR-SUB1-DOCK2 ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚ CD4+ T ç»†èƒè¿ç§»èƒ½åŠ›æ¥æ§åˆ¶è‡ªèº«å…ç–« [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305438">GSE305438 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302132">GSE302132 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºå°é¼ å•æ¬¡è‡­æ°§æš´éœ²æ¨¡å‹ä¸­è‚ºæ³¡å·¨å™¬ç»†èƒçš„ç‰¹å¼‚æ€§ååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290624">GSE290624 é€šåºœå¹³å·æ±¤æ²»ç–—æˆ–ä¸æ²»ç–—è´¥è¡€ç—‡å¤§é¼ ç›²è‚ ç»„ç»‡çš„è½¬å½•ç»„æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290518">GSE290518 é¶å‘METé…ªæ°¨é…¸æ¿€é…¶å’ŒNRF2ä¹‹é—´æ–°å‹ç›¸äº’ä½œç”¨å¯å¢å¼ºä¸‰é˜´æ€§ä¹³è…ºç™Œå¯¹ç´«æ‰é†‡çš„æ•æ„Ÿæ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289009">GSE289009 ç²’ç»†èƒæ¥æºçš„æŠµæŠ—ç´ è¯±å¯¼CMMLä¸­ç»å…¸å•æ ¸ç»†èƒé‡æ–°åˆ†å¸ƒå’Œå…ç–«æŠ‘åˆ¶</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288741">GSE288741 é€šè¿‡ CRISPR/Cas9 åŸºå› ç¼–è¾‘æŠ€æœ¯è¿ç»­æ•²å…¥è¡¨çš®ç”Ÿé•¿å› å­å—ä½“é…ä½“ç»“åˆåŸŸï¼Œå¯æ”¹å˜å…¶åœ¨å®«é¢ˆç™Œç»†èƒä¸­çš„äºšç»†èƒå®šä½å’Œç£·é…¸åŒ–æ°´å¹³ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288679">GSE288679 RNase H1 ä¾èµ–æ€§ R ç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287246">GSE287246 å¹²æ‰°Tç»†èƒè®°å¿†å¯æ”¹å–„ä½“é‡æ³¢åŠ¨å¼•èµ·çš„è¿‡åº¦ä»£è°¢ååº”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287025">GSE287025 BCAAä»£è°¢é€šè¿‡èƒ†å›ºé†‡åˆæˆä¿®é¥°ä¿ƒè¿›è‚ºç™Œçš„è‚¿ç˜¤å‘ç”Ÿ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275500">GSE275500 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [Hi-C]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275499">GSE275499 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275497">GSE275497 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270215">GSE270215ï¼šè´åˆ©æœ¨å•æŠ—æ²»ç–—ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®æ‚£è€…è¡€æ¶²å¤–å‘¨è¡€å•æ ¸ç»†èƒåŸºå› è¡¨è¾¾çš„å•ç»†èƒè½¬å½•ç»„æµ‹åºåˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263903">GSE263903 å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶å‘ç°ï¼Œæš´éœ²äºçƒŸè‰å‘³ç”µå­çƒŸçš„å°é¼ è‚ºéƒ¨ä¸­æ€§ç²’ç»†èƒåŠ¨åŠ›å­¦å‘ç”Ÿæ”¹å˜ï¼ŒTç»†èƒç»†èƒæ¯’æ€§å¢å¼ºã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255094">GSE255094 PRC2 å¯åŠ¨äºŒä»·é¶åŸºå› çš„è½¬å½•è¯±å¯¼ï¼Œä¸”ä¸ä¾èµ–äºç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶æ´»æ€§ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255093">GSE255093 PRC2 å¯åŠ¨äºŒä»·é¶åŸºå› çš„è½¬å½•è¯±å¯¼ï¼Œä¸”ä¸ä¾èµ–äºç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶æ´»æ€§ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225634">GSE225634 æ¥è‡ª M2 å·¨å™¬ç»†èƒæ¥æºçš„å¤–æ³Œä½“å¤„ç†çš„ MDA-MB-231 ä¹³è…ºç™Œç»†èƒçš„è¡¨è¾¾æ•°æ®</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274080">GSE274080 RORÎ³t+ APC éœ€è¦ç‹¬ç‰¹çš„é¡ºå¼è°ƒæ§å…ƒä»¶æ¥æŒ‡å¯¼å¯¹è†³é£ŸæŠ—åŸçš„è€å—æ€§ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317817">GSE317817 å¤šå·´èƒºç¥ç»å…ƒç‰¹å¼‚æ€§ RNA æµ‹åºæ­ç¤ºè„‘å•¡è‚½é…¶ 1 åœ¨é»è¿è›‹ç™½å¤åˆç‰©ä¸‹æ¸¸å‘æŒ¥ä½œç”¨ï¼ŒæŠ‘åˆ¶å­¦ä¹ </a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317753">GSE317753 æ‰è±†ï¼ˆLens culinaris Medik.ï¼‰ä¸­microRNAçš„å…¨åŸºå› ç»„é‰´å®šå’Œç»„ç»‡ç‰¹å¼‚æ€§åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317276">GSE317276 æ•´åˆå¤šå¹³å°ä»£è°¢ç»„å­¦æ­ç¤ºèƒ«å‰é»æ¶²æ€§æ°´è‚¿ä¸­è„‚è‚ªé…¸ä»‹å¯¼çš„ç‚ç—‡ç‰¹å¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316763">GSE316763 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [IVFP]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316762">GSE316762 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿[ç»„ç»‡ EM-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316761">GSE316761 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿[ç±»å™¨å®˜ EM-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316724">GSE316724 CHD2 çš„æ·±åº¦çªå˜æ‰«æï¼Œç”¨äºç¥ç»å‘è‚²éšœç¢çš„å˜å¼‚è§£è¯» [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316617">GSE316617 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [CUT&amp;Tag]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316581">GSE316581 HOXB2æ•²ä½åMCF-7ä¹³è…ºç™Œç»†èƒçš„è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316113">GSE316113 Ly6C+Sca-1+è™šæ‹Ÿè®°å¿†CD8+ Tç»†èƒå“åº”IL-15/RÎ±å¤åˆç‰©ä¿ƒè¿›æ…¢æ€§è‚è„ç‚ç—‡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315645">GSE315645 ç™½ç»†èƒä»‹ç´ -4:STAT6ä¿¡å·é€šè·¯é€šè¿‡æ‹®æŠ—IL-18æ„ŸçŸ¥å»¶è¿Ÿä¿æŠ¤æ€§CD8 Tç»†èƒçš„æ—è§‚è€…æ¿€æ´»</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311118">GSE311118 NSD2 é€šè¿‡ Hippo ä¿¡å·é€šè·¯çš„è¡¨è§‚é—ä¼ è°ƒæ§é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤ [Cut & Run]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311115">GSE311115 NSD2é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§Hippoä¿¡å·é€šè·¯é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310466">GSE310466 è¡¨è§‚é—ä¼ æŒç»­æ—¶é—´çš„ç§å†…å˜å¼‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310074">GSE310074 Î”Np73 äºšå‹å®šä¹‰äº†æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ä¸€ç§ç±»ä¼¼ TP53 çªå˜çš„é¢„åä¸è‰¯äºšç»„ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310000">GSE310000 äººç±»èƒŒæ ¹ç¥ç»èŠ‚çš„ snRNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309052">GSE309052 TCR-SUB1-DOCK2ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚CD4+ Tç»†èƒè¿ç§»èƒ½åŠ›æ¥è°ƒæ§è‡ªèº«å…ç–«</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307402">GSE307402 ADAR1æ²‰é»˜å¯¹äººå•æ ¸ç»†èƒæ¥æºå·¨å™¬ç»†èƒçš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307015">GSE307015 é›„æ€§é‡ç”Ÿå‹å’ŒIRF8æ•²é™¤å‹å°èƒ¶è´¨ç»†èƒçš„è½¬å½•ç»„è°±</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305852">GSE305852 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [CUT&amp;Tag]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305851">GSE305851 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [eCLIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305770">GSE305770 å…¨è½¬å½•ç»„åˆ†ææ­ç¤ºäº†æ‚£æœ‰ç–¼ç—›æ€§ç³–å°¿ç—…å‘¨å›´ç¥ç»ç—…å˜çš„å¤§é¼ èƒŒæ ¹ç¥ç»èŠ‚çš„å…³é”®è°ƒæ§ç½‘ç»œå’Œæ½œåœ¨æ²»ç–—é¶ç‚¹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305544">GSE305544 åŸºåº•å°¿è·¯ä¸Šçš®ç»†èƒä½œä¸ºè†€èƒ±ç™Œèµ·æºç»†èƒï¼Œå…¶å†…åœ¨åˆ†åŒ–ä¸ºä¸­é—´ç»†èƒå’Œä¼çŠ¶ç»†èƒçš„èƒ½åŠ›æ›´å¼º</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305440">GSE305440 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [PAS-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289271">GSE289271 è¡°è€ç›¸å…³çš„UFMylationè°ƒæ§é˜»ç¢ç§€ä¸½éšæ†çº¿è™«çš„è›‹ç™½è´¨ç¨³æ€</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288680">GSE288680 RNase H1 ä¾èµ–æ€§ R ç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶ [Stacc-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288634">GSE288634 RNase H1ä¾èµ–çš„Rç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286918">GSE286918 åµå·¢å‚¨å¤‡åŠŸèƒ½å‡é€€æ‚£è€…é¢—ç²’ç»†èƒä¸­å‘ç”Ÿçš„ä»£è°¢é‡ç¼–ç¨‹å’Œé“æ­»äº¡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275498">GSE275498 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [CUT&amp;RUN]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE259315">GSE259315 èœ‚ç‹æµ†é…¸åœ¨æºƒç–¡æ€§ç»“è‚ ç‚æ²»ç–—ä¸­çš„åº”ç”¨ï¼šé€šè¿‡ miRNA è¡¨è¾¾å’Œ NLRP3 ç‚ç—‡å°ä½“è°ƒèŠ‚ miR-210-3P/Gbp3 é€šè·¯å’Œç»†èƒç„¦äº¡ï¼ˆmiRNA-Seqï¼‰</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256425">GSE256425 èœ‚ç‹æµ†é…¸åœ¨æºƒç–¡æ€§ç»“è‚ ç‚æ²»ç–—ä¸­çš„åº”ç”¨ï¼šé€šè¿‡ miRNA è¡¨è¾¾å’Œ NLRP3 ç‚ç—‡å°ä½“è°ƒèŠ‚ miR-210-3P/Gbp3 é€šè·¯å’Œç»†èƒç„¦äº¡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246725">GSE246725 TPX2 ä½œä¸º MYCN é©±åŠ¨çš„ç¥ç»æ¯ç»†èƒç˜¤ä¸­ eIF4A æ§åˆ¶çš„ç¿»è¯‘ç¨‹åºçš„å…³é”®ä¸‹æ¸¸é¶ç‚¹[RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225870">GSE225870 åŸºäºè½¬å½•ç»„å­¦çš„æˆå¹´æ–‘é©¬é±¼ï¼ˆDanio rerioï¼‰é•¿æœŸæš´éœ²äºåŒé…šAFåè‚æ¯’æ€§æ€§åˆ«å·®å¼‚æœºåˆ¶åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117956">GSE117956 ç¥ç»è§†ç½‘è†œçš„ç»†èƒç¯å¢ƒå½±å“è¡¥ä½“å…ç–«è°ƒèŠ‚ [Hs]</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-01 21:42</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week052026/ rel=tag>Week052026</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2026-02-01/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2026-02-01</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2026-02-04/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2026-02-04</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-21/>ç§‘ç ”æ—¥æŠ¥ 2026-02-21</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-20/>ç§‘ç ”æ—¥æŠ¥ 2026-02-20</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-19/>ç§‘ç ”æ—¥æŠ¥ 2026-02-19</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-18/>ç§‘ç ”æ—¥æŠ¥ 2026-02-18</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-17/>ç§‘ç ”æ—¥æŠ¥ 2026-02-17</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (114)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (114)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week082026/ title=Week082026>Week082026 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>